The Effect of Price Control Threats on Pharmaceutical R&D Investments
Abstract/Contents
- Abstract
- This study examines how pharmaceutical R&D was impacted by two threats of price controls: Clinton's Health Security Act of 1993 and Clinton's signing of drug reimportation legislation in 2000. Firms with higher fraction of U.S. sales decreased their research intensity relative to firms with mainly foreign sales following the 1993 threat, but not the 2000 threat. Additionally, brandname pharmaceutical firms, characterized by large R&D expenditures decreased their R&D efforts post 1993 threat relative to firms that did not engage in as much innovative R&D.
Description
| Type of resource | text |
|---|---|
| Date created | June 2010 |
Creators/Contributors
| Author | Kutyavina, Marina |
|---|---|
| Primary advisor | Moser, Petra |
| Degree granting institution | Stanford University, Department of Economics |
Subjects
| Subject | Stanford Department of Economics |
|---|---|
| Subject | drug reimportation |
| Subject | R&D |
| Subject | pharmaceutical |
| Genre | Thesis |
Bibliographic information
Access conditions
- Use and reproduction
- User agrees that, where applicable, content will not be used to identify or to otherwise infringe the privacy or confidentiality rights of individuals. Content distributed via the Stanford Digital Repository may be subject to additional license and use restrictions applied by the depositor.
Preferred citation
- Preferred Citation
- Kutyavina, Marina. (2010). The Effect of Price Control Threats on Pharmaceutical R&D Investments. Stanford Digital Repository. Available at: https://purl.stanford.edu/tg517kx4122
Collection
Stanford University, Department of Economics, Honors Theses
View other items in this collection in SearchWorksContact information
- Contact
- econ@stanford.edu
Also listed in
Loading usage metrics...